141 related articles for article (PubMed ID: 37532247)
1. Organic-Solvent-Free "Lego-Like" Modular Preparation of Fab-Nondestructive Antibody-Drug Conjugates with Ultrahigh Drug-to-Antibody Ratio.
Liu Z; Zhang H; Sun J; Zheng M; Cui L; Zhang Y; Cheng J; Tang Z; Chen X
Adv Mater; 2023 Nov; 35(46):e2300377. PubMed ID: 37532247
[TBL] [Abstract][Full Text] [Related]
2. Preparation of an Ultrahigh-DAR PDL1 monoclonal antibody-polymeric-SN38 conjugate for precise colon cancer therapy.
Zhang H; Sun J; Zhang Y; Zhang Z; Wang X; Liu Z; Zhang X; Tang Z; Chen X
Biomaterials; 2023 Oct; 301():122285. PubMed ID: 37619265
[TBL] [Abstract][Full Text] [Related]
3. Design and Validation of Linkers for Site-Specific Preparation of Antibody-Drug Conjugates Carrying Multiple Drug Copies Per Cysteine Conjugation Site.
Kumar A; Mao S; Dimasi N; Gao C
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32961794
[TBL] [Abstract][Full Text] [Related]
4. Phenyldivinylsulfonamides for the construction of antibody-drug conjugates with controlled four payloads.
Wei D; Jiang Y; Mao Y; Xu Z; Chen J; Gao X; Li J; Jiang B; Chen H
Bioorg Chem; 2023 May; 134():106463. PubMed ID: 36924655
[TBL] [Abstract][Full Text] [Related]
5. Optimization of a PEGylated Glucuronide-Monomethylauristatin E Linker for Antibody-Drug Conjugates.
Burke PJ; Hamilton JZ; Jeffrey SC; Hunter JH; Doronina SO; Okeley NM; Miyamoto JB; Anderson ME; Stone IJ; Ulrich ML; Simmons JK; McKinney EE; Senter PD; Lyon RP
Mol Cancer Ther; 2017 Jan; 16(1):116-123. PubMed ID: 28062707
[TBL] [Abstract][Full Text] [Related]
6. An MMAE-loaded PDL1 active targeting nanomedicine for the precision treatment of colon cancer.
Zhang Z; Zhang H; Cui L; Wang X; Wang D; Liu Z; Zhang X; Tang Z
Biomater Sci; 2023 Jul; 11(15):5195-5204. PubMed ID: 37337707
[TBL] [Abstract][Full Text] [Related]
7. Divinylsulfonamides enable the construction of homogeneous antibody-drug conjugates.
Huang R; Sheng Y; Wei D; Lu W; Xu Z; Chen H; Jiang B
Bioorg Med Chem; 2020 Dec; 28(23):115793. PubMed ID: 33039798
[TBL] [Abstract][Full Text] [Related]
8. Custom-Designed Affinity Capture LC-MS F(ab')2 Assay for Biotransformation Assessment of Site-Specific Antibody Drug Conjugates.
Su D; Ng C; Khosraviani M; Yu SF; Cosino E; Kaur S; Xu K
Anal Chem; 2016 Dec; 88(23):11340-11346. PubMed ID: 27779866
[TBL] [Abstract][Full Text] [Related]
9. Impact of Drug Conjugation and Loading on Target Antigen Binding and Cytotoxicity in Cysteine Antibody-Drug Conjugates.
Nadkarni DV; Lee J; Jiang Q; Patel V; Sriskanda V; Dutta K; Meyer DM
Mol Pharm; 2021 Mar; 18(3):889-897. PubMed ID: 33470823
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo evaluation of cysteine and site specific conjugated herceptin antibody-drug conjugates.
Jackson D; Atkinson J; Guevara CI; Zhang C; Kery V; Moon SJ; Virata C; Yang P; Lowe C; Pinkstaff J; Cho H; Knudsen N; Manibusan A; Tian F; Sun Y; Lu Y; Sellers A; Jia XC; Joseph I; Anand B; Morrison K; Pereira DS; Stover D
PLoS One; 2014; 9(1):e83865. PubMed ID: 24454709
[TBL] [Abstract][Full Text] [Related]
11. Enzymatic conjugation using branched linkers for constructing homogeneous antibody-drug conjugates with high potency.
Anami Y; Xiong W; Gui X; Deng M; Zhang CC; Zhang N; An Z; Tsuchikama K
Org Biomol Chem; 2017 Jul; 15(26):5635-5642. PubMed ID: 28649690
[TBL] [Abstract][Full Text] [Related]
12. Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates.
Sun X; Ponte JF; Yoder NC; Laleau R; Coccia J; Lanieri L; Qiu Q; Wu R; Hong E; Bogalhas M; Wang L; Dong L; Setiady Y; Maloney EK; Ab O; Zhang X; Pinkas J; Keating TA; Chari R; Erickson HK; Lambert JM
Bioconjug Chem; 2017 May; 28(5):1371-1381. PubMed ID: 28388844
[TBL] [Abstract][Full Text] [Related]
13. HER2-targeted antibody drug conjugates for ovarian cancer therapy.
Jiang J; Dong L; Wang L; Wang L; Zhang J; Chen F; Zhang X; Huang M; Li S; Ma W; Xu Q; Huang C; Fang J; Wang C
Eur J Pharm Sci; 2016 Oct; 93():274-86. PubMed ID: 27509865
[TBL] [Abstract][Full Text] [Related]
14. Antibody Polymer Conjugates (APCs) for Active Targeted Therapeutic Delivery.
Kanjilal P; Singh K; Das R; Matte J; Thayumanavan S
Biomacromolecules; 2023 Aug; 24(8):3638-3646. PubMed ID: 37478281
[TBL] [Abstract][Full Text] [Related]
15. Development and Translational Application of an Integrated, Mechanistic Model of Antibody-Drug Conjugate Pharmacokinetics.
Sukumaran S; Zhang C; Leipold DD; Saad OM; Xu K; Gadkar K; Samineni D; Wang B; Milojic-Blair M; Carrasco-Triguero M; Rubinfeld B; Fielder P; Lin K; Ramanujan S
AAPS J; 2017 Jan; 19(1):130-140. PubMed ID: 27679517
[TBL] [Abstract][Full Text] [Related]
16. Design and characterization of homogenous antibody-drug conjugates with a drug-to-antibody ratio of one prepared using an engineered antibody and a dual-maleimide pyrrolobenzodiazepine dimer.
White JB; Fleming R; Masterson L; Ruddle BT; Zhong H; Fazenbaker C; Strout P; Rosenthal K; Reed M; Muniz-Medina V; Howard P; Dixit R; Wu H; Hinrichs MJ; Gao C; Dimasi N
MAbs; 2019 Apr; 11(3):500-515. PubMed ID: 30835621
[TBL] [Abstract][Full Text] [Related]
17. [Bioanalysis in the development of antibody-drug conjugates].
Li XL; Chen XY; Zhong DF
Yao Xue Xue Bao; 2016 Apr; 51(4):517-28. PubMed ID: 29859519
[TBL] [Abstract][Full Text] [Related]
18. Antibody Conjugations via Glycosyl Remodeling.
Toftevall H; Nyhlén H; Olsson F; Sjögren J
Methods Mol Biol; 2020; 2078():131-145. PubMed ID: 31643054
[TBL] [Abstract][Full Text] [Related]
19. High antitumor activity of Sortase A-generated anti-CD20 antibody fragment drug conjugates.
Liu W; Zhao W; Bai X; Jin S; Li Y; Qiu C; Pan L; Ding D; Xu Y; Zhou Z; Chen S
Eur J Pharm Sci; 2019 Jun; 134():81-92. PubMed ID: 30986472
[TBL] [Abstract][Full Text] [Related]
20. Recent Chemical Approaches for Site-Specific Conjugation of Native Antibodies: Technologies toward Next-Generation Antibody-Drug Conjugates.
Yamada K; Ito Y
Chembiochem; 2019 Nov; 20(21):2729-2737. PubMed ID: 30973187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
